Pegylated liposomal doxorubicin: Appraisal of its current role in the management of epithelial ovarian cancer

Cancer Management and Research

Volumn 3, Issue 1, 2011, Pages 219-225

  Markman, Maurie ^a  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

Carboplatin; Paclitaxel; Platinum resistant; Platinum sensitive; PLD

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; MACROGOL; PACLITAXEL; PLACEBO; TOPOTECAN;

ADD ON THERAPY; ALOPECIA; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; EPITHELIAL OVARY CANCER; FEMALE; HAND FOOT SYNDROME; HUMAN; LIPOSOMAL DELIVERY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE DRUG DOSE; STOMATITIS; WOUND HEALING IMPAIRMENT;

EID: 80955139792     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMR.S15558     Document Type: Review

References (33)

1. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371-1382.
2. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review with a focus on practical aspects of treatment. J Clin Oncol. 2006;24:988-994.
3. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-1425.
4. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet. 2009;374:1331-1338.
5. Burger RA, Bookman MA, Walker JL, et al. Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2010;28(18s):LBA1.
6. Perren T, Swart AM, Pfisterer J, et al. ICON 7: a Phase III Gynecologic Cancer Intergroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Presentation at ESMO, Milan, Italy; 2010.
7. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363:943-953.
8. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460-2465.
9. Markman M, Bookman M. Second-line treatment of ovarian cancer. Oncologist. 2000;6:26-35.
10. Markman M. Viewing ovarian cancer as a "chronic disease": what exactly does this mean? Gynecol Oncol. 2006;100:229-230.
11. Papahadjopoulous D, Allen TN, Gabizon A, et al. Sterically stabilized liposomes: Improvement in pharmacokinetic and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991;88:11460-11464.
12. Vaage J, Donovan D, Mayhew E, et al. Therapy of human ovarian carcinoma xenographs using doxorubicin encapsulated in sterically stabilized liposomes. Cancer. 1993;72:3671-3675.
13. Vaage J, Barbert-Guillem E, Abra R, et al. Tissue distribution and therapeutic effects of intravenous free and liposomal doxorubicin against prostatic carcinoma xenographs. Cancer. 1994;73:1478-1484.
14. Huang SK, Mayhew E, Gilani S. et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992;52:6774-6781.
15. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin (Dox-SL™): antitumor activity and unique toxicities during two complementary Phase I studies. J Clin Oncol. 1995;13:1777-1785.
16. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15: 987-993.
17. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.
18. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000;18:3093-3100.
19. Markman M, Kennedy A, Webster K, et al. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol. 2000;78:369-372.
20. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1-8.
21. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18:106-115.
22. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;13:383-393.
23. O'Byrne KS, Bliss P, Graham JD, et al. A Phase III study of Doxil/ Caelyx versus paclitaxel in platinum-treated, taxane-naïve relapsed ovarian cancer. Proc Am Soc Clin Oncol. 2002;21:203a.
24. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:2811-2818.
25. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890-896.
26. ®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer. 2009;45: 2324-2332.
27. Rose PG, Maxson JH, Fusco N, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001;82:323-328.
28. Campos SM, Penson RT, Mays AR, et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001;81: 206-212.
29. Tanyi JL, Smith JA, Ramos L, et al. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecol Oncol. 2009;114:219-224.
30. Pignata S, Scambia G, Savarese A, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin in patients with advanced ovarian cancer: final analysis of the MITO-2 randomized multicenter trial. J Clin Oncol. 2010;28(18s):952a.
31. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323-3329.
32. Markman M, Moon J, Wilczynski S, et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) Phase 3 randomized trial. Gynecol Oncol. 2010;116:323-325.
33. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28: 3107-3114.